assessment / draft protocol / final protocol / clinical management / decision analytic protocol / chemical modification / diagnostic medical devices / established real time / healthcare resources / draft decision analytic protocol / tyrosine kinase binding site / /
MedicalCondition
advanced disease / large-cell carcinoma / lung tumour / EGFR Final DAP Many M+ EGFR tumours / IV lung cancer / However squamous cell carcinoma / NSCLC tumours / metastatic disease / tumours carrying activating EGFR gene mutations / metastatic non-small cell lung cancer / non-small cell lung cancer / commonly reported cancer / infectious agent / lung adenocarcinoma / adenocarcinoma and large cell carcinoma / adenocarcinoma / breast cancers / large cell carcinomas / squamous cell carcinoma / cancer / disease / NSCLC / gastric cancers / infective disease / congenital disorders / tumour / locally advanced cancer / lung cancer / metastatic cancer / metastases / infectious disease / tumours / metastatic tumours / /
MedicalTreatment
chemotherapy / molecular therapies / face chemotherapy / /
Organization
University of Adelaide / Therapeutic Goods Administration / Australian government / National Association of Testing Authorities / DAP EGFR / Medicare / National Pathology Accreditation Advisory Committee / School of Population Health / Department of Health / Medical Services Advisory Committee / /
Person
Keedy / /
Position
Commonwealth Minister / consultant physician / Governor / Health Minister / /
Product
adenosine / PBS / EGFR29 / EGFR / /
Technology
decision analytic protocol / draft decision analytic protocol / genotyping / apoptosis / draft protocol / DNA sequencing / chemotherapy / final protocol / real time PCR protocol / /
Microsoft Word[removed]EGFR-FinalDAP.doc